Methods of inhibiting release of one or more cytokines, or inhibiting a cytokine storm, or preventing cytokine release syndrome or a cytokines storm, in a subject infected with severe acquired respiratory syndrome coronavirus 2. The method involves administering to the subject an effective amount of one or more NAD+ precursors, one or more inhibitors of stimulator of interferon genes (STING), one or more famesoid X receptor (FXR) agonists, or a combination thereof. In addition, treatment regimens involving the use of one or more NAD+ precursors, one or more STING inhibitors, one or more FXR agonists, or a combination thereof; and kits comprising pharmaceutical compositions of one or more NAD+ precursors, one or more inhibitors of stimulator of interferon genes, one or more farnesoid X receptor agonists, or combinations thereof.

The present invention provides novel compounds comprising cannabigerolic acid (CBGA) derivatives, including acids and esters, and uses thereof in the treatment of various diseases, disorders, conditions and symptoms.

A modified release oral dosage form comprising an internal phase containing terbutaline sulphate and a pharmaceutically acceptable excipient, dispersed in an external phase comprising pharmaceutically acceptable excipients.

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the SFRP5 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.

A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.

Modified G6PC (glucose-6-phosphatase, catalytic subunit) nucleic acids and glucose-6-phosphatase-α (G6Pase-α) enzymes with increased phosphohydrolase activity are described. Also described are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing modified G6Pase-α. The disclosed AAV vectors and rAAV can be used for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia), and complications thereof.

The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.

The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs. Accordingly, the fusion polypeptide of the present invention can be effectively applied to pharmaceutical drugs.

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.

The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.